| Literature DB >> 22773798 |
Robert W Carlson1, D Craig Allred, Benjamin O Anderson, Harold J Burstein, Stephen B Edge, William B Farrar, Andres Forero, Sharon Hermes Giordano, Lori J Goldstein, William J Gradishar, Daniel F Hayes, Clifford A Hudis, Steven Jay Isakoff, Britt-Marie E Ljung, David A Mankoff, P Kelly Marcom, Ingrid A Mayer, Beryl McCormick, Lori J Pierce, Elizabeth C Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L Theriault, John H Ward, Antonio C Wolff, Richard Zellars, Rashmi Kumar, Dorothy A Shead.
Abstract
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22773798 PMCID： PMC3753191 DOI： 10.6004/jnccn.2012.0086
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908